



**Supplementary Figure 6.** Comparison of outcomes according to the number of rituximab cycles administered after transplantation. Patients who were administered  $\geq 2$  cycles of rituximab after transplantation experienced significantly improved relapse-free survival (RFS) (A) and overall survival (OS) (B) compared to patients who received  $< 2$  cycles of rituximab. CR, complete remission.